Ethiopia has successfully secured the bid to establish vaccine production within its borders. The foundation stone for this project, which has received a $70 million investment, was laid at Kilinto Industrial Park. The aim is to eliminate the need for importing vaccines, which currently incurs high foreign currency expenses. Additionally, the government of Ethiopia is actively working to enhance domestic vaccine production capacity, collaborating with various stakeholders, including the Ministry of Health.
On August 20, 2023, the regulations for the establishment of Shieldvax Enterprise and Ethio Bio Pharma were approved by ministers. Shieldvax Enterprise is an umbrella enterprise that encompasses the National Veterinary Institute (NVI), a long-standing institute involved in veterinary vaccine manufacturing, and the newly established ShieldVax Enterprise. NVI has a track record of producing vital medical products, including vaccines, pharmaceuticals, medical supplies, and tests, for both human and animal use, catering to the domestic and international markets.
(Source: Capital Newspaper)
